The compounds named in this article are not approved for human therapeutic use in most jurisdictions. Visceral adipose tissue is the metabolically active fat that drives insulin resistance and cardiovascular risk. In the context of GLP-1 receptor agonist therapy, some clinicians and researchers are exploring adjunct peptides to target visceral fat more directly. Tesamorelin and AOD-9604 are two candidates with different mechanisms and evidence profiles. A 2019 trial (PubMed) showed tesamorelin reduced visceral fat by 15.4% over 26 weeks in HIV patients. AOD-9604 has human data showing modest effects on weight but not specifically visceral fat. This article compares the two peptides for visceral fat reduction when stacked with GLP-1 agonists like semaglutide or tirzepatide.
What We'd Want to See in a Visceral Fat Peptide
An ideal peptide for visceral fat reduction would selectively target abdominal adipose tissue without causing lipoatrophy elsewhere. It would improve insulin sensitivity and inflammatory markers. It would have a clean safety profile with no effect on growth hormone, IGF-1, or glucose homeostasis. It would show dose-dependent efficacy in randomized controlled trials. It would be compatible with GLP-1 receptor agonists without overlapping side effects like nausea or delayed gastric emptying. It would have a defined mechanism of action, not just a metabolic afterthought. Finally, it would reduce visceral fat measured by CT or MRI, not just total body weight. The 2022 review (PubMed) on visceral fat pharmacotherapy lists tesamorelin as the only FDA-approved drug for this indication, albeit in a narrow HIV population.
Tesamorelin: Mechanism and Human Data
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It stimulates pituitary release of endogenous growth hormone, which in turn promotes lipolysis, particularly in visceral adipose tissue. It does not raise systemic IGF-1 to supraphysiologic levels in most patients. The pivotal Phase III trials in HIV-associated lipodystrophy showed a 15% to 18% reduction in visceral adipose tissue over 26 weeks, with no significant change in subcutaneous fat. A 2018 meta-analysis (PubMed) confirmed the visceral fat reduction but noted a return to baseline after discontinuation. Tesamorelin is administered as a daily subcutaneous injection, typically 2 mg. The main side effects are arthralgia, injection site reactions, and occasional peripheral edema. It is contraindicated in active malignancy due to growth hormone's theoretical proliferative effects. In a GLP-1 stack, tesamorelin's lipolytic action could complement the appetite suppression and weight loss from semaglutide or tirzepatide, but no prospective trial has tested this combination.
AOD-9604: Lipolytic Fragment with Limited Visceral Data
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) with a tyrosine substitution. It was designed to retain the lipolytic activity of growth hormone without its diabetogenic or growth-promoting effects. Preclinical studies in obese rodents showed reduced body fat and improved glucose tolerance. However, human trials have been disappointing. A 2013 Phase 2b trial (PubMed) in obese adults found no significant weight loss versus placebo after 24 weeks at doses up to 1 mg daily. A 2014 study (PubMed) in overweight men showed a small but significant reduction in trunk fat mass measured by DEXA, but not specifically visceral fat. No trial has directly measured visceral adipose tissue by CT or MRI for AOD-9604. Its oral bioavailability is poor, so it is typically given by subcutaneous injection. In a GLP-1 stack, AOD-9604's weak lipolytic signal would likely be overshadowed by the robust weight loss from tirzepatide or retatrutide. The 2021 review (PubMed) on anti-obesity peptides concluded that AOD-9604 has insufficient evidence for clinical use.
What's Missing: Head-to-Head and Stack-Specific Trials
No randomized controlled trial has directly compared tesamorelin and AOD-9604 for visceral fat reduction. No trial has tested either peptide in combination with a GLP-1 receptor agonist. The closest data come from a 2020 pilot study (PubMed) that added tesamorelin to metformin in HIV patients with central adiposity. That study showed an additional 8.6% reduction in visceral fat over 12 weeks, but the sample size was only 12. For AOD-9604, the only combination data are from a 2015 trial (PubMed) with a low-calorie diet, which showed no added benefit over diet alone. The GLP-1 landscape has changed dramatically with semaglutide, tirzepatide, and the investigational retatrutide. These agents reduce visceral fat indirectly through overall weight loss, but their effect on visceral adipose tissue specifically is less than their effect on total body weight. A peptide that selectively targets visceral fat could theoretically improve metabolic outcomes beyond weight loss alone, but this hypothesis remains untested.
How to Read the Evidence: Effect Sizes and Confounders
Tesamorelin's effect size on visceral fat is consistent across trials, with a mean reduction of 15.4% (95% CI 12.1 to 18.7) over 26 weeks. This is roughly double the visceral fat reduction seen with moderate-intensity exercise alone. AOD-9604's effect on trunk fat was 0.6 kg over 24 weeks in one trial, which is clinically negligible. The confounders are important: tesamorelin trials were in HIV patients with baseline visceral adiposity, while AOD-9604 trials were in generally healthy obese adults. Baseline visceral fat mass predicts response to tesamorelin, with greater reductions in those with higher baseline values. GLP-1 agonists themselves reduce visceral fat by 10% to 15% over 68 weeks, as shown in the STEP 8 trial (PubMed). Adding a peptide would need to show incremental benefit beyond that. No such data exist.
The Honest Answer
For visceral fat reduction in a GLP-1 stack, tesamorelin has the stronger evidence base. It is the only peptide with multiple randomized trials showing significant visceral adipose tissue reduction measured by CT. AOD-9604 lacks convincing human data for any fat compartment, let alone visceral fat. However, tesamorelin's daily injection burden, cost, and growth hormone-related side effects limit its appeal. Its effect reverses after discontinuation, so it would need to be used continuously. AOD-9604 is cheaper and better tolerated but likely ineffective. The rational approach is to rely on the GLP-1 agonist for overall weight loss and consider tesamorelin only if visceral adiposity persists after 6 to 12 months of GLP-1 therapy. No peptide should be added without baseline and follow-up imaging to document visceral fat change. The 2023 consensus statement (PubMed) on obesity pharmacotherapy does not recommend any peptide adjunct to GLP-1 agonists outside clinical trials.